¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"active site"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
active site
Ȱ¼ººÎÀ§
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
antibody-binding site
Ç×ü°áÇÕºÎÀ§
antigen-binding site
Ç׿ø°áÇÕºÎÀ§
antigen-combining site
Ç׿ø°áÇÕºÎÀ§
antigen-recognition site
Ç׿øÀÎÁöºÎÀ§
binding site
°áÇÕºÎÀ§
combining site
°áÇÕºÎÀ§
donor site
Á¦°øºÎÀ§, °ø¿©ºÎÀ§
fragile site
Ãë¾àºÎÀ§
ligand binding site
¸®°£µå°áÇÕºÎÀ§
receptor site
¼ö¿ëüºÎÀ§
site
ºÎÀ§
telomeric site
³¡ºÐÀýºÎÀ§
artificial active immunity
Àΰø´Éµ¿¸é¿ª
active
´Éµ¿-, Àû±Ø-, Ȱ¼º-
active carbon
Ȱ¼º½¡, Ȱ¼ºÅº
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
active site
Ȱ¼ººÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
8
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
site
ºÎÀ§
antigen-binding site
Ç׿ø°áÇÕºÎÀ§
receptor site
¼ö¿ëüºÎÀ§
active carbon
Ȱ¼º½¡, Ȱ¼ºÅº
active immunity
´Éµ¿¸é¿ª
active material
Ȱ¼º¹°Áú
active oxygen
Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
active phase
Ȱ¼º±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
active site
Ȱ¼ººÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
absorption site
Èí¼öºÎÀ§
acceptor site
¼ö¿ëºÎÀ§
antibody-binding site
Ç×ü°áÇÕºÎÀ§
antigen-binding site
Ç׿ø°áÇÕºÎÀ§
antigen-combining site
Ç׿ø°áÇÕºÎÀ§
antigen-recognition site
Ç׿øÀÎÁöºÎÀ§
binding site
°áÇÕºÎÀ§
combining site
°áÇÕºÎÀ§
definitive site
Âø»óºÎÀ§
donor site
ÁִºÎÀ§, Á¦°øºÎÀ§
mutational site
µ¹¿¬º¯À̺ÎÀ§
packaging site
²Ù¸®±âºÎÀ§
privileged site
Ưº°°Ý¸®ºÎÀ§
receptor site
¼ö¿ëüºÎÀ§
site
ºÎÀ§
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
active site
Ȱ¼ºÀÚ¸®.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
absorption site
Èí¼öÁ¡
acceptor site
¼ö¿ëºÎÀ§
antibody binding site
Ç×ü°áÇÕºÎÀ§
antibody combining site
Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
antigen binding site
Ç׿ø°áÇÕºÎÀ§
antigen combining site
Ç׿ø°áÇպΠ(¡Ì¿ùêÝ»).
antigen recognition site
Ç׿ø½Äº°ºÎ.
fundic site
ÀڱùٴÚÀÓ½Å
placental site trophoblastic tumor
ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
privileged site
Ưº°°Ý¸®ºÎÀ§
receptor site
¼ö¿ëüºÎÀ§.
MR active element
ÀÚ±â°ø¸í Ȱ¼º ¿ä¼Ò
MR active nuclei
ÀÚ±â°ø¸í Ȱ¼º ÇÙ
active
Ȱµ¿¼º(üÀÔÑàõ), ´Éµ¿¼º(ÒöÔÑàõ).
active hyperemia
´Éµ¿Àû Ç÷·ùÁõ°¡(ÒöÔÑîÜúì×µñòÊ¥)
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
active site
Ȱ¼ºÀÚ¸®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
absorption site
Èí¼öÁ¡
acceptor site
¼ö¿ëºÎÀ§
antibody binding site
Ç×ü°áÇÕºÎÀ§
antibody combining site
Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
antigen binding site
Ç׿ø°áÇÕºÎÀ§
antigen combining site
Ç׿ø°áÇպΠ(¡Ì¿ùêÝ»).
antigen recognition site
Ç׿ø½Äº°ºÎ.
binding site
°áÇÕºÎÀ§.
binding site
°á ÇÕºÎÀ§.
combining site
°áÇÕºÎ(Ì¿ùêÝ»).
combining site
°áÇÕºÎÀ§
combining site of antibody
Ç×üÀÇ °áÇÕºÎ.
corporal site
ÀڱøöÅëÀÓ½Å
definitive site
Âø»óÀÚ¸®
donor site
±Þ¿©ºÎ.
´ÙÀ½
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½